Chuan Lin – Chairman, TTY Biopharm, Taiwan
Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to…
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With $1.5 billion in assets under management, the firm’s businesses include venture capital/private equity, merchant banking, and media. By leveraging the scientific and business networks of its team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, transactional support, management expertise, insight, market intelligence, and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe, and Asia.
G. Steven Burrill founded Burrill & Company as a logical extension of his 40-year involvement in the growth and prosperity of the biotechnology industry. Mr. Burrill has been an active advisor and catalyst in some of the industry’s most notable companies and transactions. Mr. Burrill’s close involvement and respected position within the industry has positioned the firm as a prominent deal-maker and facilitator of industry partnerships and alliances, all of which fosters a robust deal flow. Further contributing to this deal flow are: the scientific and business networks of its investment team; the Advisory Boards; the strategic and financial network of its limited partners; and the close relationships developed with numerous life science companies and management as a result of Burrill’s visibility, reputation, and the firm’s partnering and alliance work.
Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to…
Grace Yeh, president and founder of PharmaEngine, gives an update on the company’s recent growth and development of their second nanomedicine cancer treatment. Yeh goes on to explain the unique…
Researchers from Taiwan and the USA may have found a vaccine for the Middle East respiratory syndrome coronavirus (MERS-CoV) – a deadly emerging disease with a mortality rate of over…
Deputy Minister for Science and Technology on Taiwan Fong Chin Su gives his insights on innovation, cybersecurity, and the current state of one of the world’s most exciting biotech industries.…
Gou Jen Wang, the co-founder of Vida BioTechnology, and Bing Chen Gu, General Manager elaborate on how Vida BioTechnology provides added value to its customers by focusing on simplified use,…
Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what…
Eugene Huang, chairman, and Hua-Lin Wu, consultant of Blue Blood Biotech Corp., provide insightful information on BB-101, a protein proven to be efficient for wound healing, while sharing their vision…
Michael H.J. Lai, Founder of Body Organ Biomedical Corporation, discusses Ologen’s success as the first ever eye tissue repair product and highlights the importance of global exposure for Taiwan-based companies.…
Ken-Shwo Dai, president and CEO of Visgeneer, explains his biotech’s expertise in medtech, skincare, gene therapy and diagnostics, as well as his plans to take the company public. Can you…
Jassy Wang, CEO of MegaPro Biomedical, a nanomedicine development company specializing in developing nanoparticles and nanomicelles, discusses the evolving nanomedicine market in Taiwan and reveals the company’s plans for future…
Daniel Huang, CEO of Genomics Bioscience, Taiwan’s largest commercial genome sequencing company, and Chairman of Pharmigene, a global leader in the development and manufacturing of genetic tests, documents how he…
Yvonne Huang, VP of Aquavan, a company developing the most sophisticated high-tech green biotechnology platform for the extraction of plants, discusses their innovative technology and business scope while contributing to…
See our Cookie Privacy Policy Here
